BRIEF-United Therapeutics Corporation Announces Teton-1 Pivotal Study Of Tyvaso® Meets Primary Endpoint For Treatment Of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen In Teton-2

United Therapeutics Corporation

United Therapeutics Corporation

UTHR

0.00

March 30 (Reuters) - United Therapeutics Corp UTHR.O:

  • UNITED THERAPEUTICS CORPORATION ANNOUNCES TETON-1 PIVOTAL STUDY OF TYVASO® MEETS PRIMARY ENDPOINT FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS, EXCEEDING IMPRESSIVE TREATMENT EFFECT SEEN IN TETON-2

  • UNITED THERAPEUTICS CORP - TYVASO BENEFITS OBSERVED ACROSS ALL SUBGROUPS WITH NO NEW SAFETY SIGNALS

  • UNITED THERAPEUTICS CORP - PLANS TO SEEK PRIORITY REVIEW OF SNDA FOR TYVASO, TO BE SUBMITTED TO FDA BY END OF THIS SUMMER

Source text: ID:nBw3Wblh8a

Further company coverage: UTHR.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.